
Enabling Sequencing Anywhere - by Anyone
NEXT Generation Sequencing is moving to point-of-need
Next-generation sequencing (NGS) is increasingly shifting toward point-of-need applications due to the demand for faster results and the desire to conduct tests on-site. Sequencing and analysis can be carried out using portable, low-cost equipment. Oxford Nanopore Technologies has the first portable low-cost sequencer on the market. However, the complexity of sample processing remains a significant challenge, confining its use to specialized labs and hindering its adoption for point-of-need scenarios. Until now, sample processing technology has lagged behind the need.
Step 1: Collect Sample
Step 2: Prep Sample
Step 3: Sequence Sample
Step 4: Interpret Results
Genomics Applications Developing at a Rapid Pace
The genomics research market is rapidly growing and is projected to reach $157B by 2030. Much like the technological advances that put the power of the mainframe computer in a smartphone, we cannot begin to imagine the advances that accessible, low-cost tools for genomics research will enable.
Agnostic Diagnostics
Identify any viral or bacterial infection, including novel pathogens, and determine antibiotic resistance
Cancer
Blood biopsies can identify a wide variety of cancers at an early stage from a blood sample
Neurodegenerative Diseases
Early identification of Alzheimer’s to enable early treatment to delay disease progression
Addressing today’s gap and enabling tomorrow’s applications
Today, most DNA sequencing is done manually in the lab or on high-throughput robotic machines that cost hundreds of thousands in capital investment, making many promising applications impractical or out of reach.
NEXT Labs is working toward affordable and portable solutions for sample and library prep, which will eliminate costly and manual lab work and enable point-of-care applications.
Shown with ONT’s MinION Sequencer
Request a Briefing
Interested in collaborating on an upcoming study? We welcome inquiries from researchers, potential investors or partners.